Keiichiro Mori - My portal

Profile Information

Affiliation: assistant professor, Department of Urology, Jikei University

Researcher number: 20724701
J-GLOBAL ID: 202101021339268631
researchmap Member ID: R000029537

Research History

Apr, 2016 - Present

Jikei University
Apr, 2019 - Dec, 2021

Research fellow, Department of Urology, Medical University of Vienna
Jan, 2018 - Dec, 2018

副医長, 泌尿器科, JR東京総合病院
Apr, 2013 - Mar, 2016

Jikei University
Apr, 2011 - Mar, 2013

初期研修医, JR東京総合病院

Awards

Oct, 2022

Young Oncologist Award
Sep, 2022

慈恵医師会研究奨励賞, 東京慈恵会医科大学
Feb, 2022

The Japanese Society of Medical Oncology
Sep, 2021

EAU Young Academic Urologist UC group full member
Mar, 2021

Best Publication 2020, EAU Young Academic Urologist UC group
Jan, 2021

EAU Young Academic Urologist UC group associate member
Dec, 2020

リサーチフェローシップ, 上原記念生命科学財団
Dec, 2020

Best Researcher Award, Medical University of Vienna
Jun, 2018

Top 20 most downloaded paper, The Prostate
Jun, 2018

Best Young Publication Award
Apr, 2018

科学研究費若手研究, 独立行政法人日本学術振興会

Papers

196

Effect of a variant histology on the oncological outcomes of Japanese patients with upper tract urothelial carcinomas after radical nephroureterectomy: a multicenter retrospective study.

Naoki Uchida, Fumihiko Urabe, Yushi Suhara, Yuma Goto, Kentaro Yoshihara, Ibuki Sadakane, Yuji Yata, Shiro Kurawaki, Keiichiro Miyajima, Mimu Ishikawa …

Translational andrology and urology, 13(3) 414-422, Mar 31, 2024
Effectiveness of Magnetic Resonance Imaging/Ultrasound-guided Target Biopsy in Detecting Clinically Significant Prostate Cancer.

Gaku Kurokawa, Keiichiro Mori, Hiroshi Sasaki, Juria Nakano, Yusuke Takahashi, Kosuke Iwatani, Fumihiko Urabe, Shunsuke Tsuzuki, Yusuke Koike, Shun Sato …

Anticancer research, 44(2) 679-686, Feb, 2024
Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data.

Takafumi Yanagisawa, Keiichiro Mori, Akihiro Matsukawa, Tatsushi Kawada, Satoshi Katayama, Kensuke Bekku, Ekaterina Laukhtina, Pawel Rajwa, Fahad Quhal, Benjamin Pradere …

Cancer immunology, immunotherapy : CII, 73(2) 38-38, Jan 30, 2024
Survival outcome of chemotherapy-naïve castration-resistant prostate cancer treated with new-generation androgen receptor axis-targeted agents in real-world analysis.

Tatsuya Shimomura, Keiichiro Mori, Keiji Yasue, Akihiro Matsukawa, Wataru Fukuokaya, Takafumi Yanagisawa, Kenichi Hata, Masaya Murakami, Yusuke Koike, Jun Miki …

International journal of clinical oncology, Dec 16, 2023
上部尿路上皮癌に対するレーザー焼灼術標準化に向けての術式改良

都筑俊介, 福岡屋航, 占部文彦, 五十嵐太郎, 森啓一郎, 柳澤孝文, 佐藤峻, 鷹橋浩幸, 木村高弘

日本泌尿器内視鏡・ロボティクス学会総会, 37回 AV-2, Nov, 2023
Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta-analysis.

Keiichiro Mori, Takafumi Yanagisawa, Wataru Fukuokaya, Kosuke Iwatani, Akihiro Matsukawa, Satoshi Katayama, Benjamin Pradere, Ekaterina Laukhtina, Pawel Rajwa, Marco Moschini …

International journal of urology : official journal of the Japanese Urological Association, Oct 15, 2023
Predicting Objective Response of Pembrolizumab in Platinum-Refractory Urothelial Carcinoma Based on NLR Fluctuation and Liver Metastases.

Kyosuke Nishio, Takuya Higashio, Kazumasa Komura, Wataru Fukuokaya, Takahiro Adachi, Yosuke Hirasawa, Takeshi Hashimoto, Atsuhiko Yoshizawa, Shuya Tsuchida, Takuya Matsuda …

Oncology, Oct 13, 2023
Prognostic significance of subclassifying pathological T3 upper tract urothelial carcinoma: Results from a multicenter cohort study.

Yushi Suhara, Fumihiko Urabe, Kentaro Yoshihara, Shiro Kurawaki, Wataru Fukuokaya, Kosuke Iwatani, Yu Imai, Keigo Sakanaka, Akira Hisakane, Takashi Kurauchi …

International journal of urology : official journal of the Japanese Urological Association, Oct 12, 2023
Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study.

Takuhisa Nukaya, Kiyoshi Takahara, Atsuhiko Yoshizawa, Masanobu Saruta, Yusuke Yano, Takaya Ohno, Taizo Uchimoto, Wataru Fukuokaya, Takahiro Adachi, Shogo Yamazaki …

Clinical genitourinary cancer, Oct 1, 2023
Real-world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration-resistant prostate cancer.

Takuya Tsujino, Satoshi Tokushige, Kazumasa Komura, Wataru Fukuokaya, Takahiro Adachi, Yosuke Hirasawa, Takeshi Hashimoto, Atsuhiko Yoshizawa, Masanobu Saruta, Takaya Ohno …

Cancer medicine, 12(19) 19414-19422, Oct, 2023
Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis.

Takafumi Yanagisawa, Pawel Rajwa, Tatsushi Kawada, Keiichiro Mori, Wataru Fukuokaya, Patrik Petrov, Fahad Quhal, Ekaterina Laukhtina, Markus von Deimling, Alberto Bianchi …

The Journal of urology, 210(3) 416-429, Sep, 2023
慈恵医大関連病院における前立腺神経内分泌癌

吉原健太郎, 岩谷洸介, 下村達也, 橋本正毅, 忽滑谷悠人, 定兼伊吹, 松川明弘, 中薗実, 山崎泰輔, 占部文彦 …

泌尿器外科, 36(臨増) 847-847, Aug, 2023
東京慈恵会医科大学泌尿器科における根治的腎尿管全摘除術に関する治療成績

成田ちさと, 福岡屋航, 友政直也, 岩谷洸介, 占部文彦, 伊藤景紀, 森啓一郎, 都筑俊介, 木村章嗣, 山本順啓 …

泌尿器外科, 36(臨増) 852-852, Aug, 2023
MRI/US融合標的生検と系統的生検の意義

岩谷洸介, 佐々木裕, 占部文彦, 森啓一郎, 田代康次郎, 三木健太, 頴川晋, 木村高弘

泌尿器外科, 36(8) 946-949, Aug, 2023
Association between concomitant proton pump inhibitor use and survival of patients with metastatic prostate cancer receiving abiraterone acetate: a post-hoc analysis of pooled data from three randomized controlled trials.

Wataru Fukuokaya, Keiichiro Mori, Takafumi Yanagisawa, Kohei Akazawa, Tatsuya Shimomura, Takahiro Kimura

Prostate cancer and prostatic diseases, Jul 18, 2023
Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy.

Takafumi Yanagisawa, Kenichi Hata, Shintaro Narita, Shingo Hatakeyama, Keiichiro Mori, Yuji Yata, Takayuki Sano, Takashi Otsuka, Shuhei Hara, Keiichiro Miyajima …

The Prostate, 83(6) 563-571, May, 2023
術前血液バイオマーカーパネルによる膀胱全摘術後の腫瘍学的転帰の予測(The prediction of oncological outcomes after radical cystectomy through a panel of preoperative blood based biomarkers)

森啓一郎, 柳澤孝文, 福岡屋航, 三木淳, Shariat Shahrokh, 木村高弘

日本泌尿器科学会総会, 110回 OP12-04, Apr, 2023
プロトンポンプ阻害薬を内服する転移性前立腺癌患者におけるアビラテロンの治療効果(Effectiveness of abiraterone acetate in patients with metastatic prostate cancer receiving proton pump inhibitor)

福岡屋航, 森啓一郎, 柳澤孝文, 赤澤宏平, 下村達也, 木村高弘

日本泌尿器科学会総会, 110回 PP54-06, Apr, 2023
限局性前立腺癌に対する凍結治療の初期経験(Initial experience of primary focal cryotherapy in the management of localized prostate cancer)

岩谷洸介, 三木健太, 阪中啓吾, 占部文彦, 森啓一郎, 木村章嗣, 佐々木裕, 頴川晋, 木村高弘

日本泌尿器科学会総会, 110回 PP58-02, Apr, 2023
Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survival.

Keita Nakamori, Shogo Yamazaki, Kazumasa Komura, Wataru Fukuokaya, Takahiro Adachi, Yosuke Hirasawa, Takeshi Hashimoto, Atsuhiko Yoshizawa, Takaya Ohno, Yusuke Yano …

Clinical and translational radiation oncology, 39 100558-100558, Mar, 2023

Misc.

去勢抵抗性前立腺癌の新規ホルモン剤予後予測因子としての赤血球容積分布幅の重要性

福岡屋航, 岩谷洸介, 森啓一郎, 本田真理子, 稲葉裕之, 佐々木裕, 木村高弘, 三木健太, 頴川晋

日本泌尿器科学会総会(Web), 106th, 2018
赤血球容積分布幅は去勢抵抗性前立腺癌に対するエンザルタミドの治療効果を予測する

福岡屋航, 木村高弘, 岩谷洸介, 森啓一郎, 本田真理子, 稲葉裕之, 佐々木裕, 三木健太, 頴川晋

日本癌治療学会学術集会(Web), 56th, 2018
Nephrogenic adenoma of the bladder : A case report

70(13) 1045-1048, Dec, 2016

Research Projects

去勢抵抗性前立腺癌に対するTLR4阻害剤を用いた治療に関する検討

科学研究費助成事業若手研究, 若手研究, 日本学術振興会, Apr, 2018 - Mar, 2019

森啓一郎